👥London Life Sciences Week 2025 The busiest week in European life sciences is approaching and Optimum and Catalyst Advisors are here to help you maximise your week. Download our events schedule here to plan ahead, connect smart, and make every moment count! If you have any additional events that you would like to be included, […]
Firstly, congratulations to the team at Verona Pharma on their incredible $10bn dollar deal with Merck! And to Actithera on their oversubscribed $75.5M Series A – a great achievement in the current market. Huge congratulations also go to the incomparable Clive Cookson on receiving the Lifetime Achievement Award at the Association of British Science Writers […]
Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated Cohort 8 expected to start soon Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started Amendment of contract with HealthCare Royalty; payment of USD 20 million significantly extends cash reach Ladenburg, Germany, 24 […]
Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San Diego, […]
Ladenburg, Germany, 24 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), announces it will present its ADC candidates and ADC technology platforms at leading scientific and financial conferences throughout November. The Company’s most advanced Amanitin-based ADC product candidate, HDP-101, is currently in a Phase I/IIa trial for […]
